BMC Pediatrics (Apr 2019)

Compound heterozygous POMGNT1 mutations leading to muscular dystrophy-dystroglycanopathy type A3: a case report

  • Kondakova Olga Borisovna,
  • Krasnenko Anna Yurievna,
  • Tsukanov Kirill Yurievich,
  • Klimchuk Olesya Igorevna,
  • Korostin Dmitriy Olegovich,
  • Davidova Anna Igorevna,
  • Batysheva Tatyana Timofeevna,
  • Zhurkova Natalia Vyacheslavovna,
  • Surkova Ekaterina Ivanovna,
  • Shatalov Peter Alekseevich,
  • Ilinsky Valery Vladimirovich

DOI
https://doi.org/10.1186/s12887-019-1470-2
Journal volume & issue
Vol. 19, no. 1
pp. 1 – 8

Abstract

Read online

Abstract Background Dystroglycanopathies, which are caused by reduced glycosylation of alpha-dystroglycan, are a heterogeneous group of neurodegenerative disorders characterized by variable brain and skeletal muscle involvement. Muscle-eye-brain disease (or muscular dystrophy-dystroglycanopathy type 3 A) is an autosomal recessive disorder characterized by congenital muscular dystrophy, ocular abnormalities, and lissencephaly. Case presentation We report clinical and genetic characteristics of a 6-year-old boy affected by muscular dystrophy-dystroglycanopathy. He has severe a delay in psychomotor and speech development, muscle hypotony, congenital myopia, partial atrophy of the optic nerve disc, increased level of creatine kinase, primary-muscle lesion, polymicrogyria, ventriculomegaly, hypoplasia of the corpus callosum, cysts of the cerebellum. Exome sequencing revealed compound heterozygous mutations in POMGNT1 gene (transcript NM_001243766.1): c.1539 + 1G > A and c.385C > T. Conclusions The present case report shows diagnostic algorithm step by step and helps better understand the clinical and genetic features of congenital muscular dystrophy.

Keywords